Target intelligence / Profile preview

Rap guanine nucleotide exchange factor 5 (RAPGEF5)

Target
RAPGEF5
Molecular classification
Enzyme (specifically a guanine nucleotide exchange factor—GEF), Signal transduction molecule
01

Overview

Rap guanine nucleotide exchange factor 5 (RAPGEF5) is a member of the guanine nucleotide exchange factor (GEF) family that specifically functions as an activator for Rap1A, Rap2A, and MRAS/M-Ras GTPases[1][3]. It promotes the switch from inactive GDP-bound to active GTP-bound states, thereby facilitating signal transduction crucial for diverse biological processes including cell adhesion, migration, development, and the nuclear transport of β-catenin—a key effector in Wnt signaling[2][3]. RAPGEF5 is implicated in left-right patterning during embryogenesis and congenital heart disease[2][3]. It does not presently have known pharmacological antagonists or agonists but represents a potential target in cardiac, developmental, and oncogenic signaling pathways[2][3].

Other names
GFRKIAA0277MRGEFMR-GEFRepacguanine nucleotide exchange factor for Rap1M-Ras-regulated Rap GEFRelated to EpacRAPGEF5
02

Mechanism of action

Drugs targeting RAPGEF5 (hypothetically) would inhibit or enhance its GEF activity, modulating signal transduction by affecting GTP-bound states of Rap1A, Rap2A, MRAS (M-Ras), and β-catenin nuclear translocation[2][3].

03

Biological functions

Signal transductionCell adhesion and migrationNuclear translocation of β-catenin (in Wnt signaling)Regulation of left-right patterning during development
04

Disease associations

Congenital heart disease (including heterotaxy syndromes)CardiomyopathyFamilial isolated hypoparathyroidismCancer (potential role suggested by interaction with β-catenin, a known oncogenic mediator)
05

Safety considerations

Notably, as a regulator of critical developmental processes and Wnt/β-catenin signaling, targeting RAPGEF5 may affect cell proliferation, differentiation, and risk developmental abnormalities or tumorigenesis[2].
06

Biomarkers

Dysfunction or abnormal expression of RAPGEF5 could be explored as a biomarker for congenital heart disease, Wnt signaling dysfunction, or cancers involving β-catenin signalingNo validated clinical biomarkers.

Beyond the preview

Go deeper on Rap guanine nucleotide exchange factor 5 (RAPGEF5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rap guanine nucleotide exchange factor 5 (RAPGEF5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call